Genmab A/S
GMAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | 0.01 | -1.16 | 0.03 |
| FCF Yield | 2.83% | 0.41% | 2.03% | 0.31% |
| EV / EBITDA | 34.34 | 25.89 | 297.34 | 37.20 |
| Quality | ||||
| ROIC | 6.07% | 4.89% | 0.41% | 5.68% |
| Gross Margin | 94.32% | 93.84% | 94.13% | 94.77% |
| Cash Conversion Ratio | 1.11 | 0.15 | 1.18 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.90% | 4.58% | -3.98% | -2.70% |
| Free Cash Flow Growth | 62.05% | -81.13% | 483.12% | -84.91% |
| Safety | ||||
| Net Debt / EBITDA | -3.22 | -2.56 | -27.45 | -3.75 |
| Interest Coverage | 153.00 | 40.00 | 37.60 | 40.00 |
| Efficiency | ||||
| Inventory Turnover | 4.14 | 4.38 | 0.51 | 5.44 |
| Cash Conversion Cycle | 113.84 | 117.63 | 972.60 | 110.05 |